Get started

ABBV

Waterfall on AbbVie. ABBVBetting on a further crash in AbbVie stock price. That huge candle preempts formal volatility switch. Fractally, hard to tell from this picture, possibly a start of a C in a WXY pattern. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe.
NYSE:ABBVShort
by Rykin_Capital
AbbVie Inc, ABBV NYSE 4HNYSE:ABBV rsi in the oversold territory, which is starting to reverse to the bull side, flipped bullish on a micro timescale, falling wedge, breaking out to the upside, first target 140.75, then possible retest before 146.26. we've been in this long term downtrend channel since April 2022, I expect to break out of it, once we test 150.36 flip it as support then go for for 175.89 previous April top. fundamentals and news tend to effect this stock a lot, so with positive momentum and good news. bullish times could be ahead. Bear scenario is we test 125 before a full reset. For the current quarter, AbbVie is expected to post earnings of $3.59 per share, indicating a change of +7.8% from the year-ago quarter. The Zacks Consensus Estimate has changed -2.2% over the last 30 days. The consensus earnings estimate of $13.90 for the current fiscal year indicates a year-over-year change of +9.5%. This estimate has changed +0.2% over the last 30 days. all this is just my opinion , none of what I say should be taken as financial advice. DYOR Regards Percy
NYSE:ABBVLong
by TechnicallyBullish
ABBV ready to bounce? AbbVie Short Term We look to Buy at 138.60 (stop at 133.69) Preferred trade is to buy on dips. There is scope for mild selling at the open but losses should be limited. We therefore, prefer to fade into the dip with a tight stop in anticipation of a move back higher. Further upside is expected although we prefer to set longs at our bespoke support levels at 139.00, resulting in improved risk/reward. Our profit targets will be 152.11 and 171.00 Resistance: 146.00 / 155.00 / 172.00 Support: 139.00 / 135.00 / 126.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NYSE:ABBVLong
by Saxo
ABBV - UPDATE!I was away from TradingView for a few days, but I'm back now and continue to look at the market and look for ideas! Updating ABBV idea: Well, after the report, we teleported to shoulder level. And now several scenarios are possible: 1) Shoulder bounce 2) Shoulder breakout Which one am I more likely to go with? A shoulder breakout. But is it worth taking a position right now? I don't think it's best to be in it from the day of the report. I'm not in a position, just watching.
NYSE:ABBVShort
by Myst_Trader
2
ABBV - FUNCHARTS - Follow the TrendNote: Funcharts are interesting charts I have found that offer a potentially unique perspective on a stock. Sometimes I’ll throw something out there that you might find controversial or wrong headed. If that’s the case your 2 cents worth is most welcome. Abbvie (ABBV) listed on the US market sets up nicely as a Trend Following stock. If you are in Tradingview insert the Supertrend Strategy and change the inputs to a 50 period ATR length with a factor of 2 times ATR trailing stop. The strategy will buy when the daily closing price closes above the ATR trailing stop and go short when the price closes below the ATR trailing stop (shown in blue and red on the chart). A look at the performance summary for long trades shows 44% winning trend with a win:loss ratio of 2.22 with a profit of over 109% through the period. Whilst buy and hold was the best strategy overall the drawdown was much lower for the trend following strategy and almost as much money was made. Stock like this that trend nicely, whilst allowing you to manage downside risk can be used with a certain amount of leverage as it follows the age old mantra of letting profits run and cutting losses early. As with all trend following strategies, a low win rate but high win:loss ratio is to be expected.
NYSE:ABBVLong
by andrew.gibbs777
ABBV - Zero To Five Count And Broken TrendlineOn this monthly chart we see the 0-5 count. In my framework, the framework of the pitchfork, a 0-5 count means, that whenever 5 is reached, there is a high potential for a turn in the opposite direction, starting a new 0-5 count. On the monthly chart we also see that the CL was reached, and price seems to get rejected. So far a nice combination with the 0-5 count. Further more, the Trend line on the daily chart was broken with higher volume, three days in a row. A good confirmation of the move. Against a short is the fact, that ABBV is in a strong phase compared to the overall market. And the monthly Stochastic has not broken it's average yet. And because of this AND earnings ahead, my position will be smaller than usual, and I'm loading the boat if after earnings we see more decline in price, combined with price action. #besmartdonttradeafart
NYSE:ABBV
by Tr8dingN3rd
2
AbbVie | ABBV | Due for a CorrectionAbbVie ( NYSE:ABBV ) looks weak at resistance and may be due for a drop in the coming weeks. Pretty strong bearish divergence. Insiders selling almost $16 million worth of shares in the past month at an average of $147.87 (source: OpenInsider). If this starts to drop, support points are the 50 EMA (yellow line), $135-$136, and then the support lines / 200 EMA. Small gap to fill between $145.70 and $145.76. New drug approvals or positive company outlook could change this forecast.
NYSE:ABBVShort
by NicksAnalysis
AbbVie still bullish. ABBVGaining momentum and impulsing. This is good if you are bullish on this one. COVID paranoia is doing wonders for the pharma sector. It is very rare how a whole sector can benefit so much financially from mass hysteria. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
NYSE:ABBVLong
by Rykin_Capital
2
LFMD - WAVE C ENDING - BUY SOON OR OPTIONS LONGER TERMAll, LFMD had game changing fundamentals last quarter but still under downtrend resisance #2. This is a 3/4 retracement wave C should be ending RSI tells the story on the daily. I am watching EXTREMELY closely here. I think this is going to pop worst case is a double bottom at 7.7 or near it in which case I will absolutely be all in. Fundamnentally/valuation wise I personallly see LFMD at 14-18$ range and probably will go into 20's again from demand/lower float than most in category. As always watch the entire market first and do not enter too early. Just wait for the stars to align and for the break up to happen. Also remember almost everytime on breaks there is the first wave up but wave 2 is almost always a better and safer entry (depends how fast it moves)
NASDAQ:LFMDLong
by DigitalData